Home › SEC Filings › Press Releases
Press Releases
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| CADL | PRESS-RELEASE | neutral | 3/10 | Candel Therapeutics announced a conference call on May 15, 2026, to discuss extended follow-up data from the Phase 3 tri | May 4, 2026 |
| LENZ | PRESS-RELEASE | neutral | 1/10 | LENZ Therapeutics, Inc. announced it will report its Q1 2026 results on May 11, 2026. | May 4, 2026 |
| EVAX | PRESS-RELEASE | neutral | 1/10 | Evaxion announced it will report its Q1 2026 results on May 7, 2026. | May 4, 2026 |
| NXTC | PRESS-RELEASE | neutral | 4/10 | NextCure announced initiation of dose optimization for its CDH6-directed ADC SIM0505 in platinum-resistant ovarian cance | May 4, 2026 |
| AXSM | PRESS-RELEASE | mixed | 6/10 | Axsome reported Q1 2026 revenue of $191.2M (57% YoY growth, slight beat vs $190.7M consensus), but GAAP EPS of -$1.26 mi | May 4, 2026 |
| KRYS | PRESS-RELEASE | bullish | 6/10 | Krystal Biotech reported strong Q1 2026 results with VYJUVEK revenue up 32% YoY to $116.4M and diluted EPS of $1.83, up | May 4, 2026 |
| MCRB | PRESS-RELEASE | neutral | 3/10 | Seres Therapeutics presented preclinical data for SER-603, a next-generation live biotherapeutic for IBD, at DDW 2026. T | May 4, 2026 |
| AURA | PRESS-RELEASE | bearish | 5/10 | Aura Biosciences announced an underwritten public offering of common stock and pre-funded warrants, with a 30-day underw | May 4, 2026 |
| AURA | PRESS-RELEASE | mixed | 5/10 | Aura Biosciences announced the appointment of Natalie Holles as CEO and President, succeeding founder Elisabet de los Pi | May 4, 2026 |
| SCLX | PRESS-RELEASE | neutral | 4/10 | Scilex announces payment date of May 26, 2026 for a dividend of Dream Bowl Meme Coin tokens at 5 tokens per share, distr | May 4, 2026 |
| ARVN | PRESS-RELEASE | bullish | 8/10 | Arvinas (ARVN) announced FDA approval of VEPPANU (vepdegestrant), the first-ever PROTAC therapy, for ER+/HER2- ESR1-muta | May 1, 2026 |
| RZLT | PRESS-RELEASE | mixed | 5/10 | Rezolute released expanded Phase 3 sunRIZE study data showing clinically meaningful glycemic improvements on multiple CG | May 1, 2026 |
| HYPD | PRESS-RELEASE | neutral | 1/10 | Hyperion DeFi, Inc. announced it will host a conference call on May 14 to discuss its Q1 results. | May 1, 2026 |
| VXRT | PRESS-RELEASE | bearish | 7/10 | Vaxart reported a significant Q4 2025 EPS miss of -$0.10 versus the $0.02 consensus, a 600% negative surprise. No revenu | May 1, 2026 |
| AMTX | PRESS-RELEASE | neutral | 1/10 | Aemetis, Inc. announced it will report its Q1 2026 results on May 7, 2026. | May 1, 2026 |
| PHAT | PRESS-RELEASE | neutral | 1/10 | Phathom Pharmaceuticals announced its participation in the Digestive Disease Week (DDW) 2026 annual meeting, including a | May 1, 2026 |
| IFRX | PRESS-RELEASE | neutral | 1/10 | InflaRx N.V. announced it will report its Q1 2026 results on May 7, 2026. | May 1, 2026 |
| AXSM | PRESS-RELEASE | bullish | 8/10 | Axsome Therapeutics announced FDA approval of AUVELITY for agitation associated with Alzheimer's disease dementia, a maj | May 1, 2026 |
| ESPR | PRESS-RELEASE | bullish | 7/10 | Esperion has agreed to be acquired by ARCHIMED for $3.16 per share in cash at closing, plus contingent milestone payment | May 1, 2026 |
| MPLT | PRESS-RELEASE | neutral | 4/10 | MapLight Therapeutics announced completion of enrollment in the Phase 2 ZEPHYR trial for ML-007C-MA in schizophrenia (30 | May 1, 2026 |
| MOLN | PRESS-RELEASE | neutral | 4/10 | Molecular Partners announced publication of Phase 1 data for MP0317, a tumor-localized CD40 agonist, in Nature Cancer. T | May 1, 2026 |
| RYTM | PRESS-RELEASE | bullish | 7/10 | Rhythm Pharmaceuticals received European Commission approval for IMCIVREE (setmelanotide) to treat acquired hypothalamic | May 1, 2026 |
| LYB | PRESS-RELEASE | mixed | 6/10 | LyondellBasell reported Q1 2026 GAAP EPS of $0.38 (vs consensus $0.28, beat) but GAAP net income of $125M was down 29% Y | May 1, 2026 |
| LYB | PRESS-RELEASE | neutral | 4/10 | LyondellBasell completed the sale of select European olefins and polyolefins assets to AEQUITA, a key step in its Europe | May 1, 2026 |
| RNTX | PRESS-RELEASE | bearish | 8/10 | Rein Therapeutics priced a $50M underwritten public offering of 50M shares at $1.00/share, with an underwriter option fo | Apr 30, 2026 |
| HELP | PRESS-RELEASE | neutral | 3/10 | Helus Pharma announced a collaboration with TARA Mind to support recruitment for its Phase 3 HLP003 program in major dep | Apr 30, 2026 |
| COAG | PRESS-RELEASE | neutral | 5/10 | Hemab Therapeutics priced its IPO at $18.00 per share, offering 16.75M shares for gross proceeds of ~$301.5M, with an un | Apr 30, 2026 |
| INCR | PRESS-RELEASE | mixed | 6/10 | InterCure reported FY2025 revenue of NIS 270M (+13% YoY), a net loss of NIS 37M (improved from NIS 73M loss in 2024), an | Apr 30, 2026 |
| FBLG | PRESS-RELEASE | neutral | 5/10 | FibroBiologics reported Q1 2026 EPS of -$0.60, a 55.7% beat vs consensus of -$1.35, but net loss was flat YoY at $5.0M. | Apr 30, 2026 |
| MEOH | PRESS-RELEASE | bearish | 7/10 | Methanex reported Q1 2026 EPS of $0.30, a 28.6% miss versus the $0.42 consensus, with no revenue figure provided in the | Apr 30, 2026 |